Atlanta, GA, April 19, 2023 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced that it will release its financial results for the three and twelve month periods ended January 31, 2023 on Wednesday, April 26, 2023 after the close of the financial markets.
The Company will conduct a conference call on Thursday, April 27, 2023 at 9:00 AM ET to review results and provide a corporate update. Interested parties can access the call by joining the live webcast:
click here to register. You can also join by phone by dialing 877-407-8291.
A replay of the conference call will be available from Thursday, April 27, 2022 at 12:00 PM ET to Thursday, May 4, 2023 at 12:00 PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 13738301. An online replay of the presentation will also be available for six months following the presentation in the Investor Relations section of the Streamline website, www.streamlinehealth.net.
About Streamline
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net.
Company Contact
Jacob Goldberger
Director, Investor Relations and FP&A
303-887-9625
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.29 |
Daily Change: | -0.0019 -0.65 |
Daily Volume: | 244,181 |
Market Cap: | US$17.080M |
April 29, 2024 February 07, 2024 December 13, 2023 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB